| 產品名稱： |
Regorafenib (BAY 73-4506) |
| 中文別名： |
瑞格菲尼;瑞格非尼;瑞戈非尼;4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;4-[4-({[4-氯-3-(三氟甲基)苯基]氨甲酰基}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;Regorafenib（BAY73-4506） 抑制劑;科研實驗瑞格非尼;瑞戈非尼-13C-D3;瑞格非尼靶向藥;瑞格非尼標準品;瑞格非尼固體狀;瑞格非尼無水物;瑞格非尼雜質;瑞格菲尼雜質;五氟丙酸鈉鹽;醫(yī)藥級瑞格非尼;阿爾法育亨賓;育亨賓堿;瑞格菲尼無水物;瑞格菲尼及中間體;BAY 73-4506/ 瑞格非尼/ 4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;REGORAFENIB 瑞格非尼;4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基 }羰基)氨基]苯氧基}-N-甲基吡啶-2-甲酰胺;4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨;瑞格非尼 1KG |
| 英文名稱： |
Regorafenib |
| 英文別名： |
4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide;BAY 73-4506;4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;BAY 73-4506(Regorafenib);4-[4-({[4-chioro-3-(trifluoroMethyl)phenyl]carbaMoyl}aMino)-3-fluorophenoxy]-pyridine-2-carboxylic acid MethylaMide;Regorafenib (BAY 73-4506);4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]-3-fluorophenoxy]-N-Methyl-2-pyridinecarboxaMide;4-[4-[N'-(4-Chloro-3-trifluoroMethylphenyl)ureido]-3- fluorophenoxy]pyridine-2-carboxylic Acid MethylaMide;4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;Regorafenib;Regorafenib（BAY73-4506）;Regorafenib hydrate;BAY734506;FREE BASE;4-(4-(3-(4-chloro-3-(trifluoroMethyl)phenyl)ureido)-3-fluorophenoxy)-N-MethylpicolinaMide;REGORAFENIB BAY 73-4506 BAYER HEALTHCARE (SEE ALSO COLORECTAL, LUNG, STOMACH) PHASE II(REGORAFENIB) PHARMACEUTICALS (888) 842-2937WAYNE, NJ |
| 品牌： |
PERFEMIKER |
| CAS號： |
755037-03-7 |
| 分子式： |
C??H??CLF?N?O? |
| 分子量： |
482.82 |
| 純度： |
99% |
| 詳細描述： |
Regorafenib (BAY 73-4506)是多靶點抑制劑，對VEGFR1，VEGFR2，VEGFR3，PDGFRβ，Kit，RET和Raf-1的IC50分別為13 nM，4.2 nM，46 nM |
滬公網安備31011402010658號 
